NCT07123506View on ClinicalTrials.gov

Beta-blockers for Prevention of Supraventricular Arrhythmia Following PFO Closure

NANot yet recruitingINTERVENTIONAL

Enrollment

350

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

May 3, 2029

Conditions

Atrial FibrillationAtrial FlutterTachycardia, SupraventricularHeart Septal Defects, Atrial

Interventions

DRUG

Beta-blocker treatment group

After PFO closure, the beta-blocker treatment group will receive an extended-release beta-blocker, either bisoprolol or nebivolol, at a dose of 1.25 mg QD for 30 days.

DRUG

Non-treatment group

After PFO closure, the non-treatment group will not receive a beta-blocker.

Trial Locations (1)

Unknown

Severance Cardiovascular Hospital, Yonsei University Health System, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER

NCT07123506 - Beta-blockers for Prevention of Supraventricular Arrhythmia Following PFO Closure | Biotech Hunter | Biotech Hunter